Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (111-120 of 223) with videos related to

Pageof 23
Sort By:
Blood|May 16, 2014
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinibDominik Wodarz, Naveen Garg, Natalia L Komarova, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Blood|March 1, 2019
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemiaPablo Elías Morande, Mariela Sivina, Angimar Uriepero, et al.
Cancer|November 21, 2015
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaPhilip A Thompson, Susan M O'Brien, Lianchun Xiao, et al.
Hemasphere|May 28, 2024
First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysisPaolo Ghia, Carolyn Owen, John N Allan, et al.
Blood|December 20, 2011
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoSabine Ponader, Shih-Shih Chen, Joseph J Buggy, et al.
Cancer|April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicityMax J Gordon, Jade E Jones, Binsah George, et al.
Blood|October 23, 2024
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRDEkaterina Kim, Shih-Shih Chen, Mariela Sivina, et al.
Cancers|January 21, 2023
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 StudyJennifer A Woyach, Paul M Barr, Thomas J Kipps, et al.
Pageof 23

Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
Blood|May 16, 2014
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinibDominik Wodarz, Naveen Garg, Natalia L Komarova, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Blood|March 1, 2019
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemiaPablo Elías Morande, Mariela Sivina, Angimar Uriepero, et al.
Cancer|November 21, 2015
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaPhilip A Thompson, Susan M O'Brien, Lianchun Xiao, et al.
Hemasphere|May 28, 2024
First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysisPaolo Ghia, Carolyn Owen, John N Allan, et al.
Blood|December 20, 2011
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoSabine Ponader, Shih-Shih Chen, Joseph J Buggy, et al.
Cancer|April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicityMax J Gordon, Jade E Jones, Binsah George, et al.
Blood|October 23, 2024
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRDEkaterina Kim, Shih-Shih Chen, Mariela Sivina, et al.
Cancers|January 21, 2023
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 StudyJennifer A Woyach, Paul M Barr, Thomas J Kipps, et al.
Pageof 23